Sertraline dosing trends in children and adolescents stratified by CYP2C19 genotype

Jacob T. Brown, David B. Gregornik, Alissa Jorgenson, Dave Watson, Samuel A. Roiko, Jeffrey R. Bishop

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Aim: Sertraline is a CYP2C19 substrate commonly prescribed to children with anxiety. Materials & methods: This medical record review examined dosing trends and treatment discontinuation in children prescribed sertraline with documented CYP2C19 genotypes. Variables collected included age, weight, diagnosis, concomitant medications, initial sertraline dose, dose changes and CYP2C19 genotypes. Results: A total of 90 individuals (average age: 10.5 years; 40% female) were included. Nearly 80% were prescribed sertraline for anxiety. Initial weight-adjusted doses were similar, but mean weight-adjusted doses of sertraline were 65% higher in increased metabolizers (1.5 mg/kg/day) compared with normal metabolizers (0.91 mg/kg/day; p = 0.067) at the second dose change. Conclusion: While all children started at a similar sertraline dose, different trends in prescribed doses were observed across CYP2C19 genotypes at subsequent dose changes.

Original languageEnglish (US)
Pages (from-to)247-253
Number of pages7
Issue number4
StatePublished - Mar 2022

Bibliographical note

Publisher Copyright:
© 2022 Future Medicine Ltd.


  • CYP2C19
  • children
  • pharmacogenetics
  • pharmacogenomics
  • sertraline


Dive into the research topics of 'Sertraline dosing trends in children and adolescents stratified by CYP2C19 genotype'. Together they form a unique fingerprint.

Cite this